Table 3.
Serum/plasma expression of miRNAs correlated with clinical phenotypes in DM.
| miRNAs | Regulation | Clinical phenotypes | Ref |
|---|---|---|---|
| miR-4442 | Up | Skeletal disease activities | [23] |
| miR-146a | Down | Inflammation | [8] |
| Let-7b | Up | [11] | |
| miR-3907 | Up | Disease activity | |
| miR-4299 | Down | ||
| miR-7 | Down | Gottron's eruption | [26] |
| miR-223 | Down | Gottron's papules | [24] |
| miR-23b-3p | Down | CK | Our study |
| miR-146a-5p | Down | CRP | |
| miR-146b-5p | Up | ESR, CRP, and DM complicated with cancer | |
| miR-150-5p | Down | Anti-MDA5 and anti-NXP2 antibody |
DM: dermatomyositis; CK: creatine kinase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; anti-MDA5: anti-melanoma differentiation-associated gene 5; anti-NXP2: anti-nuclear matrix protein-2